Association between expression of embryonic lethal abnormal vision-like protein HuR and cyclooxygenase-2 in oral squamous cell carcinoma

Head and Neck

Volumn 33, Issue 5, 2011, Pages 627-637

  Cha, Jeong Dan ^a   Li, Shengjin ^a   Cha, In Ho ^a  

^a Yonsei University College of Dentistry   (South Korea)

Author keywords

AU rich elements; cyclooxygenase 2; human ELAV like protein HuR; leptomycin B; oral squamous cell carcinoma

Indexed keywords

CYCLOOXYGENASE 2; HUR PROTEIN; LEPTOMYCIN B; SMALL INTERFERING RNA;

ADULT; ARTICLE; CANCER SURVIVAL; DISEASE ASSOCIATION; DISTANT METASTASIS; FAR WESTERN BLOTTING; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MOUTH CARCINOMA; ORAL SQUAMOUS CELL CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA;

ANTIGENS, SURFACE; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CYCLOOXYGENASE 2; CYTOPLASM; FATTY ACIDS, UNSATURATED; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MOUTH NEOPLASMS; MULTIVARIATE ANALYSIS; PROGNOSIS; RNA, MESSENGER; RNA, SMALL INTERFERING; RNA-BINDING PROTEINS; SEX FACTORS; TUMOR CELLS, CULTURED;

EID: 79954479159     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.21507     Document Type: Article

References (64)

1. Shiboski CH, Schmidt BL, Jordan RC,. Tongue and tonsil carcinoma: increasing trends in the U.S. population ages 20-44 years. Cancer 2005; 103: 1843-1849. (Pubitemid 40563256)
2. Roland NJ, Caslin AW, Nash J, Stell PM,. Value of grading squamous cell carcinoma of the head and neck. Head Neck 1992; 14: 224-229.
3. Stanko P, Satko I, Czako L, Beno M, Danko J, Zmeko S,. Squamous cell carcinoma of the oral cavity. Bratisl Lek Listy 2007; 108: 292-296.
4. Zavras AI, Laskaris C, Kittas C, Laskaris G,. Leukoplakia and intraoral malignancies: female cases increase in Greece. J Eur Acad Dermatol Venereol 2003; 17: 25-27. (Pubitemid 36163649)
5. Barzan L, Talamini R, Franchin G, et al. Changes in presentation and survival of head and neck carcinomas in Northeastern Italy, 1975-1998. Cancer 2002; 95: 540-552. (Pubitemid 34810179)
6. Singh A, Kapur S, Chattopadhyay I, et al. Cytokeratin immunoexpression in esophageal squamous cell carcinoma of high-risk population in Northeast India. Appl Immunohistochem Mol Morphol 2009; 17: 419-424.
7. Rogers SN, Brown JS, Woolgar JA, et al. Survival following primary surgery for oral cancer. Oral Oncol 2009; 45: 201-211.
8. Eckert AW, Lautner MH, Dempf R, Schubert J, Bilkenroth U,. Prognostic factors for oral squamous cell carcinoma. [Article in German] Chirurg 2009; 80: 138-143.
9. Zhao D, Pan J, Li XQ, Wang XY, Tang C, Xuan M,. Intratumoral lymphangiogenesis in oral squamous cell carcinoma and its clinicopathological significance. J Oral Pathol Med 2008; 37: 616-625.
10. UÇurluer G, Ozyurt SC, Aksaray F, Aslan N, HabiboÇlu R, Tümöz M,. Prognostic factors and survival rates in oral cavity cancers. [Article in Turkish] Kulak Burun Bogaz Ihtis Derg 2006; 16: 64-71.
11. Karadeniz A, Saynak M, Kadehci Z, et al. The results of combined treatment (surgery and postoperative radiotherapy) for tongue cancer and prognostic factors. [Article in Turkish] Kulak Burun Bogaz Ihtis Derg 2007; 17: 1-6.
12. Whiteside TL,. Immunobiology and immunotherapy of head and neck cancer. Curr Oncol Rep 2001; 3: 46-55.
13. Larsen SR, Johansen J, SÃrensen JA, Krogdahl A,. The prognostic significance of histological features in oral squamous cell carcinoma. J Oral Pathol Med 2009; 38: 657-662.
14. Bilde A, von Buchwald C, Dabelsteen E, Therkildsen MH, Dabelsteen S,. Molecular markers in the surgical margin of oral carcinomas. J Oral Pathol Med 2009; 38: 72-78.
15. Jaworska M, KoÅosza Z, Liszka J, et al. Prognostic molecular markers in oral and lip squamous cell carcinoma - evaluation of expression and its significance. [Article in Polish] Otolaryngol Pol 2008; 62: 175-181.
16. Pereira MC, Oliveira DT, Landman G, Kowalski LP,. Histologic subtypes of oral squamous cell carcinoma: prognostic relevance. J Can Dent Assoc 2007; 73: 339-344.
17. Sasaki T, Moles DR, Imai Y, Speight PM,. Clinico-pathological features of squamous cell carcinoma of the oral cavity in patients <40 years of age. J Oral Pathol Med 2005; 34: 129-133. (Pubitemid 40293220)
18. Martinez-Conde R, Aguirre JM, Burgos JJ, Rivera JM,. Clinicopathological factors in early squamous cell carcinoma of the tongue and floor of the mouth, in Biscay (the Basque Country, Spain). [Article in English, Spanish] Med Oral 2001; 6: 87-94. (Pubitemid 32238309)
19. Raybaud H, Odin G, Fafet A, Santini J, Monteil RA,. Genic alterations in oral and head and neck squamous cell carcinomas: analysis of international literature. [Article in French] Pathol Biol (Paris) 2003; 51: 176-184. (Pubitemid 36734147)
20. Xu J, Gimenez-Conti IB, Cunningham JE, et al. Alterations of p53, cyclin D1, Rb, and H-ras in human oral carcinomas related to tobacco use. Cancer 1998; 83: 204-212. (Pubitemid 28317798)
21. Camacho M, León X, Fernández-Figueras MT, Quer M, Vila L,. Prostaglandin E(2) pathway in head and neck squamous cell carcinoma. Head Neck 2008; 30: 1175-1181.
22. Kasza Z, Fetalvero KM, Ding M, et al. Novel signaling pathways promote a paracrine wave of prostacyclin-induced vascular smooth muscle differentiation. J Mol Cell Cardiol 2009; 46: 682-694.
23. Rüegg C, Dormond O, Mariotti A,. Endothelial cell integrins and COX-2: mediators and therapeutic targets of tumor angiogenesis. Biochim Biophys Acta 2004; 1654: 51-67. (Pubitemid 38230931)
24. Harris RE,. Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung. Inflammopharmacology 2009; 17: 55-67.
25. Hermanova M, Karasek P, Nenutil R, et al. Clinicopathological correlations of cyclooxygenase-2, MDM2, and p53 expressions in surgically resectable pancreatic invasive ductal adenocarcinoma. Pancreas 2009; 38: 565-571.
26. Zafirellis K, Agrogiannis G, Zachaki A,. Prognostic value of COX-2 immunohistochemical expression evaluated by quantitative image analysis in colorectal cancer. APMIS 2008; 116: 912-922.
27. Takatori H, Natsugoe S, Okumura H, et al. Cyclooxygenase-2 expression is related to prognosis in patients with esophageal squamous cell carcinoma. Eur J Surg Oncol 2008; 34: 397-402. (Pubitemid 351381291)
28. Athanassiadou P, Grapsa D, Athanassiades P, et al. The prognostic significance of COX-2 and survivin expression in ovarian cancer. Pathol Res Pract 2008; 204: 241-249. (Pubitemid 351377530)
29. Yamac D, Celenkoglu G, Coskun U, et al. Prognostic importance of COX-2 expression in patients with colorectal cancer. Pathol Res Pract 2005; 201: 497-502. (Pubitemid 41131390)
30. Hales DB, Zhuge Y, Lagman JA, et al. Cyclooxygenases expression and distribution in the normal ovary and their role in ovarian cancer in the domestic hen (Gallus domesticus). Endocrine 2008; 33: 235-244.
31. Matsumoto Y, Ishiko O, Deguchi M, Nakagawa E, Ogita S,. Cyclooxygenase-2 expression in normal ovaries and epithelial ovarian neoplasms. Int J Mol Med 2001; 8: 31-36.
32. Dixon DA,. Dysregulated post-transcriptional control of COX-2 gene expression in cancer. Curr Pharm Des 2004; 10: 635-646. (Pubitemid 38292390)
33. Inoue H, Taba Y, Miwa Y, Yokota C, Miyagi M, Sasaguri T,. Transcriptional and posttranscriptional regulation of cyclooxygenase-2 expression by fluid shear stress in vascular endothelial cells. Arterioscler Thromb Vasc Biol 2002; 22: 1415-1420.
34. Appleby SB, Ristimäki A, Neilson K, Narko K, Hla T,. Structure of the human cyclo-oxygenase-2 gene. Biochem J 1994; 302 (Pt 3): 723-727. (Pubitemid 24289307)
35. Dean JL, Sully G, Wait R, Rawlinson L, Clark AR, Saklatvala J,. Identification of a novel AU-rich-element-binding protein which is related to AUF1. Biochem J 2002; 366 (Pt 3): 709-719.
36. Dixon DA, Kaplan CD, McIntyre TM, Zimmerman GA, Prescott SM,. Post-transcriptional control of cyclooxygenase-2 gene expression. The role of the 3â-untranslated region. J Biol Chem 2000; 275: 11750-11757. (Pubitemid 30237739)
37. Mazan-Mamczarz K, Gartenhaus RB,. Post-transcriptional control of the MCT-1-associated protein DENR/DRP by RNA-binding protein AUF1. Cancer Genomics Proteomics 2007; 4: 233-239.
38. Peng SS, Chen CY, Xu N, Shyu AB,. RNA stabilization by the AU-rich element binding protein, HuR, an ELAV protein. EMBO J 1998; 17: 3461-3470. (Pubitemid 28279518)
39. Doller A, Pfeilschifter J, Eberhardt W,. Signalling pathways regulating nucleo-cytoplasmic shuttling of the mRNA-binding protein HuR. Cell Signal 2008; 20: 2165-2173.
40. Brennan CM, Steitz JA,. HuR and mRNA stability. Cell Mol Life Sci 2001; 58: 266-277. (Pubitemid 32217358)
41. Xiao L, Rao JN, Zou T, et al. Polyamines regulate the stability of activating transcription factor-2 mRNA through RNA-binding protein HuR in intestinal epithelial cells. Mol Biol Cell 2007; 18: 4579-4590. (Pubitemid 350060183)
42. Papadaki O, Milatos S, Grammenoudi S, Mukherjee N, Keene JD, Kontoyiannis DL,. Control of thymic T cell maturation, deletion and egress by the RNA-binding protein HuR. J Immunol 2009; 182: 6779-6788.
43. Lu JY, Schneider RJ,. Tissue distribution of AU-rich mRNA-binding proteins involved in regulation of mRNA decay. J Biol Chem 2004; 279: 12974-12979. (Pubitemid 38445873)
44. Denkert C, Koch I, von Keyserlingk N, et al. Expression of the ELAV-like protein HuR in human colon cancer: association with tumor stage and cyclooxygenase-2. Mod Pathol 2006; 19: 1261-1269. (Pubitemid 44268197)
45. López de Silanes I, Lal A, Gorospe M,. HuR: post-transcriptional paths to malignancy. RNA Biol 2005; 2: 11-13.
46. Nabors LB, Gillespie GY, Harkins L, King PH,. HuR, a RNA stability factor, is expressed in malignant brain tumors and binds to adenine- and uridine-rich elements within the 3â untranslated regions of cytokine and angiogenic factor mRNAs. Cancer Res 2001; 61: 2154-2161. (Pubitemid 32692041)
47. Nassar A, Radhakrishnan A, Cabrero IA, Cotsonis G, Cohen C,. COX-2 expression in invasive breast cancer: correlation with prognostic parameters and outcome. Appl Immunohistochem Mol Morphol 2007; 15: 255-259. (Pubitemid 47329915)
48. Juuti A, Louhimo J, Nordling S, Ristimäki A, Haglund C,. Cyclooxygenase-2 expression correlates with poor prognosis in pancreatic cancer. J Clin Pathol 2006; 59: 382-386.
49. Niesporek S, Kristiansen G, Thoma A, et al. Expression of the ELAV-like protein HuR in human prostate carcinoma is an indicator of disease relapse and linked to COX-2 expression. Int J Oncol 2008; 32: 341-347. (Pubitemid 351188300)
50. Lim SJ, Kim HJ, Kim JY, Park K, Lee CM,. Expression of HuR is associated with increased cyclooxygenase-2 expression in uterine cervical carcinoma. Int J Gynecol Pathol 2007; 26: 229-234. (Pubitemid 46986054)
51. Mrena J, Wiksten JP, Thiel A, et al. Cyclooxygenase-2 is an independent prognostic factor in gastric cancer and its expression is regulated by the messenger RNA stability factor HuR. Clin Cancer Res 2005; 11: 7362-7368. (Pubitemid 41507695)
52. Denkert C, Weichert W, Pest S, et al. Overexpression of the embryonic-lethal abnormal vision-like protein HuR in ovarian carcinoma is a prognostic factor and is associated with increased cyclooxygenase 2 expression. Cancer Res 2004; 64: 189-195. (Pubitemid 38114097)
53. Denkert C, Weichert W, Winzer KJ, et al. Expression of the ELAV-like protein HuR is associated with higher tumor grade and increased cyclooxygenase-2 expression in human breast carcinoma. Clin Cancer Res 2004; 10: 5580-5586. (Pubitemid 39100499)
54. Erkinheimo TL, Lassus H, Sivula A, et al. Cytoplasmic HuR expression correlates with poor outcome and with cyclooxygenase 2 expression in serous ovarian carcinoma. Cancer Res 2003; 63: 7591-7594. (Pubitemid 37466678)
55. Kang CH, Chiang PH, Huang SC,. Correlation of COX-2 expression in stromal cells with high stage, high grade, and poor prognosis in urothelial carcinoma of upper urinary tracts. Urology 2008; 72: 153-157.
56. Huang WZ, Fu JH, Wang DK, et al. Overexpression of cyclooxygenase-2 is associated with chemoradiotherapy resistance and prognosis in esophageal squamous cell carcinoma patients. Dis Esophagus 2008; 21: 679-684.
57. Mazan-Mamczarz K, Hagner PR, Corl S, et al. Post-transcriptional gene regulation by HuR promotes a more tumorigenic phenotype. Oncogene 2008; 27: 6151-6163.
58. Yoo PS, Mulkeen AL, Cha CH,. Post-transcriptional regulation of vascular endothelial growth factor: implications for tumor angiogenesis. World J Gastroenterol 2006; 12: 4937-4942. (Pubitemid 44323260)
59. Westmark CJ, Bartleson VB, Malter JS,. RhoB mRNA is stabilized by HuR after UV light. Oncogene 2005; 24: 502-511. (Pubitemid 40188597)
60. Sengupta S, Jang BC, Wu MT, Paik JH, Furneaux H, Hla T,. The RNA-binding protein HuR regulates the expression of cyclooxygenase-2. J Biol Chem 2003; 278: 25227-25233. (Pubitemid 37548687)
61. Sully G, Dean JL, Wait R, et al. Structural and functional dissection of a conserved destabilizing element of cyclo-oxygenase-2 mRNA: evidence against the involvement of AUF-1 [AU-rich element/poly(U)-binding/degradation factor-1], AUF-2, tristetraprolin, HuR (Hu antigen R) or FBP1 (far-upstream-sequence- element-binding protein 1). Biochem J 2004; 377 (Pt 3): 629-639. (Pubitemid 38221834)
62. Jang BC, Muñoz-Najar U, Paik JH, Claffey K, Yoshida M, Hla T,. Leptomycin B, an inhibitor of the nuclear export receptor CRM1, inhibits COX-2 expression. J Biol Chem 2003; 278: 2773-2776. (Pubitemid 36801177)
63. Lim SJ, Lee SH, Joo SH, Song JY, Choi SI,. Cytoplasmic expression of HuR is related to cyclooxygenase-2 expression in colon cancer. Cancer Res Treat 2009; 41: 87-92.
64. Erkinheimo TL, Sivula A, Lassus H, et al. Cytoplasmic HuR expression correlates with epithelial cancer cell but not with stromal cell cyclooxygenase-2 expression in mucinous ovarian carcinoma. Gynecol Oncol 2005; 99: 14-19. (Pubitemid 41354577)